Skip to main content

Peninsula startup’s all-star lineup, fresh off $197M round, circles next-generation cell therapies against cancer, other diseases

The former StartX accelerator company has raised $300 million over four years with the hopes of taking cell therapies into genetic diseases and autoimmune disorders.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.